entity,start_date,end_date,context,AARSRAPPORT_html,AARSRAPPORT_pdf,AARSRAPPORT_xml,AdditionsToPropertyPlantAndEquipment,AddressOfAuditorDistrictName,AddressOfAuditorPostCodeIdentifier,AddressOfAuditorStreetBuildingIdentifier,AddressOfAuditorStreetName,AddressOfReportingEntityDistrictName,AddressOfReportingEntityPostCodeIdentifier,AddressOfReportingEntityStreetBuildingIdentifier,AddressOfReportingEntityStreetName,AddressOfSubmittingEnterprisePostcodeAndTown,AddressOfSubmittingEnterpriseStreetAndNumber,AddresseeOfAuditorsReportOnAuditedFinancialStatements,AdministrativeExpenses,ClassOfReportingEntity,ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement,ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults,DateOfApprovalOfAnnualReport,DateOfGeneralMeeting,DescriptionOfAuditor,DescriptionOfClassOfIssuedShares,DescriptionOfMethodsOfCurrentTaxReceivablesAndLiabilities,DescriptionOfMethodsOfDividends,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAdministrativeExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInvestments,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncome,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses,DescriptionOfQualificationsOfAuditedFinancialStatements,DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod,DisclosureOfAnyUncertaintyConnectedWithRecognitionOrMeasurement,DisclosureOfContingentLiabilities,DisclosureOfLiabilitiesUnderLeases,DisclosureOfReceivables,DividendPaid,GrossResult,IdentificationNumberCvrOfAuditFirm,IdentificationNumberCvrOfReportingEntity,IdentificationNumberCvrOfSubmittingEnterprise,IdentificationNumberOfAuditor,IdentificationOfApprovedAnnualReport,IncreaseDecreaseOfInvestmentsThroughNetExchangeDifferencesEquity,InformationOnReportingClassOfEntity,InformationOnTypeOfSubmittedReport,InterestExpenseAssignedToGroupEnterprises,ManagementsStatementAboutManagementsReview,NameAndSurnameOfAuditor,NameAndSurnameOfChairmanOfGeneralMeeting,NameAndSurnameOfMemberOfExecutiveBoard,NameOfAuditFirm,NameOfReportingEntity,NameOfSubmittingEnterprise,OtherFinanceIncome,OtherInterestExpenses,OtherOperatingIncome,PlaceOfSignatureOfStatement,PrecedingReportingPeriodStartDate,PredingReportingPeriodEndDate,ProfitLoss,ProfitLossAfterAttributableToMinorityInterest,ProfitLossFromOrdinaryActivitiesBeforeTax,ProfitLossFromOrdinaryOperatingActivities,ProposedDividendRecognisedInEquity,RecommendationForApprovalOfAnnualReportByGeneralMeeting,RegisteredOfficeOfReportingEntity,ReportingPeriodEndDate,ReportingPeriodStartDate,ResearchAndDevelopmentExpenditure,RestOfOtherFinanceExpenses,Revenue,SignatureOfAuditorsDate,SignatureOfAuditorsPlace,TaxExpenseOnOrdinaryActivities,TelephoneNumberOfAuditor,TelephoneNumberOfReportingEntity,TitleOfMemberOfExecutiveBoard,TitleOfMemberOfSupervisoryBoard,TypeOfAuditorAssistance,_id,_index,_score,cvrNummer,indlaesningsId,indlaesningsTidspunkt,offentliggoerelsesTidspunkt,offentliggoerelsestype,omgoerelse,regNummer,regnskabsperiode_slutDato,regnskabsperiode_startDato,sagsNummer,sidstOpdateret,Assets,CashAndCashEquivalents,ContributedCapital,CurrentAssets,DeferredIncomeAssets,Equity,FixturesFittingsToolsAndEquipment,LiabilitiesAndEquity,LiabilitiesOtherThanProvisions,LongtermInvestmentsAndReceivables,LongtermLiabilitiesOtherThanProvisions,LongtermPayablesToGroupEnterprises,NoncurrentAssets,OtherLongtermReceivables,OtherReceivables,OtherShorttermPayables,OtherShorttermReceivables,PlantAndMachinery,PropertyPlantAndEquipment,RetainedEarnings,ShorttermLiabilitiesOtherThanProvisions,ShorttermReceivables,ShorttermReceivablesFromGroupEnterprises,ShorttermTaxPayables,ShorttermTaxPayablesToGroupEnterprises,ShorttermTaxReceivablesFromGroupEnterprises,ShorttermTradePayables,AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment,PropertyPlantAndEquipmentGross,NameAndSurnameOfMemberOfSupervisoryBoard,DepreciationOfPropertyPlantAndEquipment,DisposalsOfPropertyPlantAndEquipment,ReversalsOfImpairmentLossesAndDepreciationOfDisposedPropertyPlantAndEquipment,NominalValueOfIssuedShares,NumberOfIssuedShares
27394752,2016-01-01,2016-12-31,D-2016,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,5786000.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,49052000.0,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,2958000.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,234000.0,63000.0,334539000.0,HillerÃ¸d,2016-01-01,2016-12-31,294360000.0,294360000.0,334531000.0,337318000.0,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,40487000.0,3021000.0,49052000.0,2018-03-19,KÃ¸benhavn,40171000.0,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2016-01-01,2016-12-31,D-2016-dim-FixturesFittingsTool,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2016-01-01,2016-12-31,D-2016-dim-PlantAndMachineryMem,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2016-01-01,2016-12-31,D-2016-dim-ProposedDividendReco,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,152900000.0,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2016-01-01,2016-12-31,D-2016-dim-ProposedDividendReco.1,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2016-01-01,2016-12-31,D-2016-dim-RetainedEarningsMemb,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,141460000.0,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2016-01-01,2016-12-31,D-2016-dim-RetainedEarningsMemb.1,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,141460000.0,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2016-12-31,2016-12-31,I-2016-E,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,360029000.0,3494000.0,2500000.0,357254000.0,5439000.0,230260000.0,317000.0,360029000.0,129769000.0,115000.0,69046000.0,69046000.0,2775000.0,115000.0,320000.0,3091000.0,320000.0,2343000.0,2660000.0,74860000.0,60723000.0,353760000.0,347343000.0,33375000.0,6796000.0,658000.0,17461000.0,,,,,,,,
27394752,2016-12-31,2016-12-31,I-2016-E-dim-ContributedCapitalMe,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,2500000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2016-12-31,2016-12-31,I-2016-E-dim-FixturesFittingsTool,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,317000.0,,,,,,,,,-342000.0,659000.0,,,,,,
27394752,2016-12-31,2016-12-31,I-2016-E-dim-OtherReceivablesMemb,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,115000.0,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2016-12-31,2016-12-31,I-2016-E-dim-PlantAndMachineryMem,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,2343000.0,,,,,,,,,-3732000.0,6075000.0,,,,,,
27394752,2016-12-31,2016-12-31,I-2016-E-dim-ProposedDividendReco,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,152900000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2016-12-31,2016-12-31,I-2016-E-dim-RetainedEarningsMemb,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,74860000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2017-01-01,2017-12-31,D-2017,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,6390000.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,39575000.0,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,2837000.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,7675000.0,152000.0,397000.0,HillerÃ¸d,2016-01-01,2016-12-31,3404000.0,3404000.0,7433000.0,2747000.0,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,30835000.0,2989000.0,39575000.0,2018-03-19,KÃ¸benhavn,4029000.0,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2017-01-01,2017-12-31,D-2017-dim-Bestyrelsesmedlem1,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Jens Morten Fogh,,,,,
27394752,2017-01-01,2017-12-31,D-2017-dim-Bestyrelsesmedlem2,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Claes Magnus Andersson,,,,,
27394752,2017-01-01,2017-12-31,D-2017-dim-Bestyrelsesmedlem3,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mark Parry-Billings,,,,,
27394752,2017-01-01,2017-12-31,D-2017-dim-Direktionsmedlem01,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2017-01-01,2017-12-31,D-2017-dim-FixturesFittingsTool,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,63000.0,-77000.0,74000.0,,
27394752,2017-01-01,2017-12-31,D-2017-dim-PlantAndMachineryMem,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,790000.0,-458000.0,431000.0,,
27394752,2017-01-01,2017-12-31,D-2017-dim-ProposedDividendReco,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2017-01-01,2017-12-31,D-2017-dim-RetainedEarningsMemb,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,3404000.0,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2017-01-01,2017-12-31,D-2017-dim-RetainedEarningsMemb.1,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,3404000.0,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2017-01-01,2017-12-31,D-2017-dim-Revisionsvirksomhed0,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2017-01-01,2017-12-31,D-2017-dim-Revisionsvirksomhed0.1,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2017-12-31,2017-12-31,I-2017-E,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,168416000.0,20934000.0,2500000.0,166097000.0,210000.0,80885000.0,251000.0,168416000.0,87531000.0,116000.0,72686000.0,72686000.0,2319000.0,116000.0,54000.0,2001000.0,54000.0,1952000.0,2203000.0,78385000.0,14845000.0,145163000.0,144241000.0,1774000.0,6492000.0,658000.0,4578000.0,,,,,,,2500000.0,2500000.0
27394752,2017-12-31,2017-12-31,I-2017-E-dim-ContributedCapitalMe,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,2500000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2017-12-31,2017-12-31,I-2017-E-dim-FixturesFittingsTool,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,251000.0,,,,,,,,,-331000.0,582000.0,,,,,,
27394752,2017-12-31,2017-12-31,I-2017-E-dim-Kapitalklasse01,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2500000.0,2500000.0
27394752,2017-12-31,2017-12-31,I-2017-E-dim-OtherReceivablesMemb,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,116000.0,,,,,,,,,,,,,,,,,,,,,,,,,
27394752,2017-12-31,2017-12-31,I-2017-E-dim-PlantAndMachineryMem,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,,,,,,,,,,,,,,1952000.0,,,,,,,,,-4091000.0,6043000.0,,,,,,
27394752,2017-12-31,2017-12-31,I-2017-E-dim-RetainedEarningsMemb,,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzUyLzljLzc0L2M2LzExNDgtNDRmNi1hNDRjLTA4OGFjMzUwZDUzOQ.pdf,http://regnskaber.virk.dk/25749372/ZG9rdW1lbnRsYWdlcjovLzAzLzU4L2UwLzg5L2M2LzlkNTYtNDE1ZS1iODkxLWNhZmQwYjQ3ZjM3ZQ.xml,426000.0,KÃ¸benhavn C,900.0,6.0,Weidekampsgade Postboks 1600,HillerÃ¸d,3400.0,12 C,Roskildevej,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Zymenex A/S,,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",2018-03-19,2018-04-17,State Authorised Public Accountant,Share Capital,"Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,"Administrative costs comprise expenses incurred for the Entityâs administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies as well as amortisation, depreciation and impairment losses relating to property, plant and equipment.",Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme etc. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities.,"Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.",Revenue consist of founding from the Parent company CHIESI FARMACEUTICI S.p.A. for the research and development as well as administration cost that the company have based on a cost plus agreement.,"Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.","We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","Except for the above mentioned about the transfer of the business no events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.","Mid-february the board of directors determined to cease the activity of Zymenex A/S, and transfer relevant activities to one or more entities within the Chiesi Farmaceutici S.p.A. Group. The transfer will be effective mid-2018. Subsequent to the transfer of activity, management will commence a solvent liquidation of the company. Management does not expect that the transfer will impact the measurement of assets and liabilities of the company 31.12.2017. Likewise, management believes that the company can be liquidated by means of a solvent liquidation and has therefore prepared the 2017 financial statements using the accounting policies applied in prior periods.","The Entity participates in a Danish joint taxation arrangement in which Zymenex Holding A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore alternatively liable from the financial year 2013 for income taxes etc for the jointly taxed entities, but only for the share by which the Entity is included in the Group, and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for these entities. The total known net liability of the jointly taxed entities under the joint taxation arrangement is evident from the administration companyâs financial statements.",The Entity has entered into operating lease agreements with the non-cancellable period up to 15 months. At the balance sheet date is estimated lease obligations total t. DKK 1.143.,"The company is taxed jointly with other Danish Companies in the group, and, as from the 2013 finical year, the company is liable for tax claims on a pro rata basis and most comply with any obligations to withhold tax at source on interest, royalties and dividends for the jointly taxed companies. The maximum liability totals an amount corresponding to the share of the capital in the company which is owned directly or indirectly by the ultimate parent. As at the balance date, the total liability amounts to DKK 0.",-152900000.0,,33963556.0,27394752.0,33963556.0,mne27790,The Board of Directors and the Executive Board have today considered and approved the annual report of Zymenex A/S for the financial year 01.01.2017 - 31.12.2017.,121000.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Flemming Larsen,"Lars Terp, Lawyer",Mark Parry-Billings,Deloitte Statsautoriseret Revisionspartnerselskab,Zymenex A/S,Deloitte Statsautoriseret Revisionspartnerselskab,,,,HillerÃ¸d,2016-01-01,2016-12-31,,,,,152900000.0,We recommend the annual report for adoption at the Annual General Meeting.,HillerÃ¸d,2017-12-31,2017-01-01,,,,2018-03-19,KÃ¸benhavn,,36 10 20 30,48250054.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:25331520,indberetninger-20180424,2.5118406,27394752.0,AWLdsQjgx8uVRSOdf1VS,2018-04-19T11:36:43.445Z,2018-04-19T11:36:28.765Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AJ-35-AY,2018-04-19T11:36:29.094Z,,,,,,78385000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
